Skip Navigation


Rheumatology Advance Access originally published online on October 14, 2008
Rheumatology 2008 47(12):1775-1779; doi:10.1093/rheumatology/ken385
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/12/1775    most recent
ken385v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Choi, S. T.
Right arrow Articles by Lee, S.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, S. T.
Right arrow Articles by Lee, S.-K.
Related Collections
Right arrow Spondylarthropathies
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis

S. T. Choi1, J. H. Kim1, E.-J. Kang1, S.-W. Lee1, M.-C. Park1, Y.-B. Park1 and S.-K. Lee1

1Division of Rheumatology, Department of Internal Medicine, Institute for Immunology and Immunologic Diseases, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.

Correspondence to: S.-K. Lee, Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-ku, Seoul 120-752, South Korea. E-mail: sookonlee{at}yuhs.ac


  Abstract

Objectives. To determine whether osteopontin (OPN) is increased in patients with AS and to investigate its relationship to inflammatory disease activity and bone remodelling process.

Methods. This cross-sectional study included 30 patients with AS and 23 age- and sex-matched healthy controls. We assessed clinical characteristics and laboratory parameters including the ESR, CRP, lipid profiles, the Bath AS disease activity index (BASDAI) and the Bath AS radiographic index (BASRI). To evaluate bone metabolism, we tested ALP, OCN and C-telopeptide of type I collagen (CTX-I). Plasma levels of OPN, TNF-{alpha} and IL-6 were measured by ELISA, and mRNA expression in peripheral blood mononuclear cells (PBMCs) was performed by RT–PCR. Changes in OPN level were also evaluated in eight patients after the treatment with a TNF-{alpha} blocker.

Results. Patients with AS had significantly higher plasma OPN, TNF-{alpha} and IL-6 levels and more mRNA expression than healthy controls. Plasma OPN levels were correlated with serum ALP, OCN and CTX-I levels, but not with ESR, CRP, lipid profiles, BASDAI or BASRI. Treatment with a TNF-{alpha} blocker did not alter OPN levels, although it reduced the disease activity.

Conclusions. Patients with AS had higher levels of OPN compared with controls. The plasma OPN level was correlated with serum ALP, OCN and CTX-I levels, but not with disease activity in AS. OPN might be involved in bone remodelling rather than in inflammation in AS.

KEY WORDS: Osteopontin, Ankylosing spondylitis, Bone remodelling, Disease activity

Submitted 23 May 2008; revised version accepted 4 September 2008.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.